A respected biotechnology company, Stemedica Cell Technologies, Inc., remains at the forefront of regenerative medicine through innovations in stem cells and biological compounds. Additionally, Stemedica Cell Technologies produces some of these advancements through its recently formed cardiology subsidiary named CardioCell LLC.

1. By Stemedica

2.  A respected biotechnology company,
Stemedica Cell Technologies, Inc., remains at
the forefront of regenerative medicine
through innovations in stem cells and
biological compounds. Additionally,
Stemedica Cell Technologies produces some
of these advancements through its recently
formed cardiology subsidiary named
CardioCell LLC.

3.  n February 2014, CardioCell announced that the
Company will begin a Phase IIa clinical trial in the
United States and Phase III clinical trial in
Kazakhstan for the treatment of acute myocardial
infarction using Stemedica’s allogeneic ischemic
tolerant mesenchymal stem cells. The U.S. based
trial will occur at the University of California San
Diego, and at Mercy Gilbert Medical Center and
Chandler Regional Medical Center in Arizona. The
researchers, who are currently recruiting
participants, will post the latest information
about the trials at Clinicaltrials.gov. More
information can also be found at
www.Stemedica.com